An estimator for treatment comparisons among survivors in randomized trials

Douglas Hayden, Donna K. Pauler, David Schoenfeld

Research output: Contribution to journalReview articlepeer-review

56 Scopus citations

Abstract

In clinical trials of advanced-stage disease it is often of interest to perform treatment comparisons for endpoints which are defined only for survivors. Examples include time on ventilation in ventilation studies, change in quality of life in health-related quality-of-life studies, and duration of response to therapy in therapeutic trials. Randomized treatment comparisons for these endpoints cannot be performed because the outcomes are only defined in the nonrandomly selected subgroup of survivors. We propose a new evaluation of the survivor average causal effect (SACE) for treatment comparisons of this nature. We provide an estimator of SACE in the presence of no unmeasured confounders, a nontestable assumption, which identifies SACE. We also outline a sensitivity analysis for exploring robustness of conclusions to deviations from this assumption. We apply this method to duration of ventilation in a clinical trial of acute respiratory distress syndrome.

Original languageEnglish (US)
Pages (from-to)305-310
Number of pages6
JournalBiometrics
Volume61
Issue number1
DOIs
StatePublished - Mar 2005

Keywords

  • Counterfactual
  • Explainable nonrandom survival
  • Survivor average causal effect

ASJC Scopus subject areas

  • Statistics and Probability
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Agricultural and Biological Sciences(all)
  • Applied Mathematics

Fingerprint Dive into the research topics of 'An estimator for treatment comparisons among survivors in randomized trials'. Together they form a unique fingerprint.

Cite this